読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$1.23
−$0.07 · -5.38%
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
前日終値
$1.23
−$0.07 · -5.38%
日中の時刻はETです。市場データは遅延する場合があります。
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
日中レンジ
現在 $1.23
52週レンジ
現在 $1.23
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
28
割高
センチメント
43
まちまち
リスク
51
やや高いリスク
モメンタム
30
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
日中レンジ
現在 $1.23
52週レンジ
現在 $1.23
営業利益
純利益
| 指標（CAD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | — | 6.23万 CAD |
| 売上原価 | — | — | 18.74万 CAD | 16.22万 CAD | 17.43万 CAD |
| 粗利益 | — | — | −18.74万 CAD | −16.22万 CAD | −11.2万 CAD |
| 研究開発 | 1401.85万 CAD | 1401.21万 CAD | 1073.22万 CAD | 1398.83万 CAD | 859.42万 CAD |
| 販売・一般管理 | 2019.59万 CAD | 2589.14万 CAD | 1155.36万 CAD | 1634.29万 CAD | 2186.22万 CAD |
| 営業費用 | 3431.63万 CAD | 4027.67万 CAD | 2228.58万 CAD | 3033.13万 CAD | 3045.64万 CAD |
| 受取利息 | 72.64万 CAD | 119.33万 CAD | 203.85万 CAD | 123.76万 CAD | 10.6万 CAD |
| 減価償却費と償却費 | 10.2万 CAD | 37.31万 CAD | 24.84万 CAD | 21.99万 CAD | 22.04万 CAD |
| 営業利益 | −3431.63万 CAD | −4027.67万 CAD | −2247.32万 CAD | −3049.35万 CAD | −3056.84万 CAD |
| 純利益 | −3381.89万 CAD | −3667.73万 CAD | −2122.28万 CAD | −2281.75万 CAD | −2501.32万 CAD |
会社概要が更新されました 2026年10月11日.
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
